海南机场 20250311 摘要 • 海南机场正积极推进封关运作，预计 2025 年中或年底进行具体测试，涉 及口岸监管服务系统、反走私综合执法系统等信息化项目。封关形式尚未 明确，机场主要负责软硬件准备，预计年底前完成封关。 • 2024 年海南离岛免税销售额约 309 亿元，公司参与的五家免税店销售额 占比约 16%-17%，达 50 多亿元。2025 年海南力争离岛免税店销售额达 到 520 亿元，同比增长 10%以上，但市场压力依然存在。 • 公司参与的免税店表现各异：美兰机场免税店销售额降幅低于全岛平均， 凤凰机场免税店同比增长，CDF 日月广场中免店和全球精品店线下零售降 幅略高于全岛平均，整体市场份额稳定。 • 2025 年海南岛内三大机场预计开通 90 条以上国际航线，国际旅客吞吐量 预计达 240 万人次以上，显著高于 2024 年的 185 万人次，覆盖 RCEP 伙 伴国家。凤凰机场 2024 年完成约 64 万国际和地区旅客吞吐量，目标 2025 年达到 80 万以上。 • 海南自贸港政策，如 59 国免签及放宽入境政策，对提升海南吸引力有积 极作用。省政府鼓励拓展国际航线，第七航权使 ...

博济医药 20250312 摘要 • 公司临床板块业务收入已位列上市公司前二，虽行业竞争加剧导致订单毛 利率和整体利润率下降，但公司选择牺牲部分利润以提高市场占有率和品 牌影响力。 • 同源康 9,591 项目海外权益由常州润诺与参股公司推进，主要海外专利已 授权，正与合作方探讨境外开发，并尝试在美国申请 IND 批文，潜在交易 价值预计低于 FA 测算的 5-6 亿美元。 • 同源康针对脑转移适应症的研究取得突破性成功，肺癌脑转移二期临床试 验完成并取得初步结果，有望附条件上市，预计近期提交上市许可申请； 晚期肺癌一线治疗三期临床试验预计 2026 年有结果。 • 生物药和 CRO 行业面临融资困难和医保支付压力，但政策逐渐向创新药倾 斜，license-out 持续增长带来现金流，下半年市场或回暖，客户付款情 况改善。 • 公司积极寻找并购标的，补强研发服务领域，关注疫苗、血液制品及 mRNA 技术平台等领域，增强创新药物发现能力，为客户提供更多研发服 务及创新药苗子。 Q&A 请介绍一下国际医药公司近期的经营情况及项目进展。 2024 年虽然整个行业面临较大压力，但国际医药公司仍较好地完成了既定目 标。 ...

＂低利率+高波动＂时代的债市投资策略——申万宏源 ·2025 资本市场春季策略会 20250311 摘要 • 模型通过六个关键指标（制造业 PMI、PMI 出厂价格、季节性因子及差分 处理后的价格指标）刻画经济和市场特征，简化 KG0 算法，寻找与当前相 似的历史时期，预测未来收益率变动。自 2019 年以来，模型预测方向胜 率超 70%，幅度偏差逐渐收窄至 5BP 左右。 • 模型采用中位数而非平均值，以减少极端值干扰，并选择 2019 年以来的 数据作为样本区间，因该时期宏观经济、金融监管及货币政策框架发生重 大变化，更具参考意义。尽管市场整体向好，但模型在收益率上下行预测 中均表现出较高胜率。 • 模型缺陷在于无法提前捕捉突发政策变化，如 2024 年 7 月降息和 10 月 稳增长信号。为改进模型，设计了久期轮动、替换竞价指数和增加杠杆等 回测方案，旨在验证并优化模型落地效果，提高应用效果。 • 回测结果显示，基础轮动策略年化收益较基准一提高 1.1%，替换竞价指 数策略提高 1.3%，增加杠杆策略夏普比最高，表明模型对资本利得有显 著贡献。比较基准设计为短债和长债指数平均值（久期 4.6 年），高于 ...

蔚蓝锂芯 摘要 • 蔚蓝理性 2024 年总营收 67.56 亿元，其中锂电池业务增长最快，营收达 26 亿元，同比增长 58%，毛利率达 22%，显著修复 13.51 个百分点。 LED 和金属材料业务营收分别为 23 亿元和 24.5 亿元，分别同比增长 23%和 6%。 • 2024 年，工具赛道出货占比接近 80%，两轮车及容量型占比超 10%，清 洁电器等其他应用占比近 10%。预计 2025 年工具赛道占比降至 70%， 容量型占比超 20%，清洁电器等占比 10%，总出货量目标 7 亿颗。 • BBU 产品 2024 年出货量约 50 万颗，单价近 2 美元；机器人和机器狗出 货量近 60 万颗，单价约 8 美元。预计 2025 年 BBU 出货量翻倍增长，主 要客户为台湾和泰国工厂，国内与麦格米特等客户正在测试。 • 机器人业务方面，公司是语数公司 60%的供应商，并与三星合作测试 18,650 和 21,700 电池。未来人形机器人应用机会较小，但特定机器人或 有应用，21,700 规格或成主流。 • EV to 项目仍处于陪跑期，未设定 2025 年具体出货目标，主要支持下游 客户主机设计 ...

Summary of the Conference Call for Chuanwei Energy Company Overview - Chuanwei Power is a state-owned electricity asset integration platform in Sichuan Province, holding a 50% stake. As of Q3 2024, the net assets are approximately 42 billion yuan, with 48% stake in Yalong River Hydropower Company accounting for about 32 billion yuan, representing 75% of the company's assets [3][4]. Core Assets and Financial Performance - The core asset is the 48% stake in Yalong River Hydropower, which has exclusive development rights in the Yalong River basin, with a planned total installed capacity of 30 million kilowatts. The company contributes approximately 5 billion yuan in investment income annually [2][4]. - Yalong River Hydropower has a stable performance with an average electricity price higher than the provincial average due to its regulatory reservoirs, which provide annual investment returns of about 5 billion yuan [5][6]. Market Dynamics and Competitive Position - Short-term demand for electricity in Sichuan and Yunnan is strong, with limited competition from thermal power, resulting in minimal impact from electricity price declines. The increase in trading prices during peak periods is favorable for Yalong River [2][6]. - The competitive pressure in the electricity sector is limited for Chuanwei, as the demand for hydropower in Southwest China remains stable, and the company has strong bargaining power regarding electricity prices [6][7]. Revenue and Growth Projections - Revenue growth for Yalong River is expected to be around 3% to 4% from 2025 to 2026, with improved water inflow partially offsetting any negative impacts [9][10]. - The company has significant growth potential with approximately 7 million kilowatts of undeveloped projects expected to be operational between 2030 and 2035 [11]. Cost Management and Financial Strategy - Yalong River's financial strategy includes replacing high-interest loans, which is expected to save about 200 million yuan annually in financial costs, contributing marginally to performance growth [10][12]. - The company has a long-term dividend yield of approximately 3.3%, which could increase to 3.84% with an improved payout ratio. The free cash flow return rate is around 15%, higher than competitors [12][13]. Investment Highlights and Market Sentiment - The current valuation presents a good buying opportunity, with a reset cost valuation of about 100 billion yuan compared to the current market value [13][14]. - Recent declines in the hydropower sector's stock prices are attributed to market style rotation rather than changes in the company's operational status [15]. Future Outlook and Asset Integration - There is potential for asset integration within the group, which may include additional hydropower assets from other subsidiaries [17]. - The company is actively developing integrated wind and solar projects to enhance utilization hours and return levels [11]. Conclusion - Chuanwei Energy is well-positioned in the hydropower sector with stable revenue streams, strong growth potential, and effective cost management strategies, making it an attractive investment opportunity in the current market environment.

Summary of Conference Call Records Company and Industry Overview - **Company**: 爱美客 (Aimeike) - **Industry**: Medical Aesthetics Key Points and Arguments 1. **Acquisition of Region Biot**: Aimeike acquired 85% of South Korea's Region Biot for $190 million, with plans to acquire the remaining 15% later, marking a significant step in building an overseas investment platform [1][3][4] 2. **Region Biot's Core Products**: Region Biot's main products include S feel and Power view, both of which are approved in multiple countries. S feel leads the market in Taiwan with a 30% share, while Power view targets male intimate area filling [1][5] 3. **Financial Performance of Region Biot**: In 2023, Region Biot reported revenue of 81.99 million RMB and a profit of 50 million RMB, with a net profit margin of 61%. However, the net profit margin is expected to drop to 41% in the first three quarters of 2024 due to increased depreciation from capacity expansion [1][6][7] 4. **Market Growth**: The global regenerative product market is projected to grow at a CAGR of 14% from 2023 to 2027, reaching $840 million by 2027, with increasing consumer acceptance in China [1][9] 5. **Capacity Expansion**: Region Biot's capacity is limited in 2024, but a new factory is expected to be operational by Q2 2025, increasing total capacity to 1.2 million units, which could lead to revenues close to 1 billion RMB if fully utilized [1][10] 6. **Investment Logic**: Aimeike's investment strategy leverages its dual attributes in the medical aesthetics industry, combining pharmaceutical and consumer characteristics, which positions it for high growth [2] 7. **Projected Financials**: Aimeike maintains profit forecasts of 2.6 billion RMB for 2025 and 3.2 billion RMB for 2026, with a target market valuation of 79.3 billion RMB based on a 30x earnings multiple [3][18] 8. **Impact of Direct Sales Model**: Transitioning to a direct sales model in China could significantly enhance profitability, with potential revenues of 1.9 billion RMB and net profits of 740 million RMB [13][14] 9. **Negotiation with Jiangsu Wuzhong**: Aimeike's negotiation with Jiangsu Wuzhong, which holds exclusive rights for S feel in China until 2032, may lead to a shift in distribution strategy, potentially increasing profitability [14][15] 10. **Strategic Significance of Acquisition**: The acquisition of Region Biot is a milestone for Aimeike, enhancing its global presence and product innovation capabilities, particularly in a fast-evolving market like South Korea [16][22] Additional Important Insights - **Market Dynamics**: The high-end medical aesthetics market has faced challenges, with companies like Allergan and Galderma reporting lower-than-expected performance due to a decline in demand in China [16][21] - **Profit Margin Considerations**: As Aimeike expands internationally, initial profit margins may decrease due to reliance on distribution models, but overall profitability could still improve with new product contributions [19][20] - **Future Growth Potential**: Despite current pressures, there is optimism for recovery in high-end medical aesthetics products, particularly as macroeconomic conditions improve [21]

宏和科技 20250311 摘要 • 电子布价格虽在 2024 年有所回升，但仍低于 2021-2022 年水平，全年 均价小幅上涨。公司在行业集体提价前已率先提价，并获得客户认可，主 要因原材料电子纱价格上涨及下游需求强劲，预计全年提价幅度与行业水 平一致，约为 10%。 • 7,628 产品受益于汽车电子需求增长，占比显著提升，涨幅较大。薄布、 超薄布等特殊规格产品也进行了不同程度的调价，客户对涨价接受度高， 订单量保持稳定。与日本客户合作产品因原有利润空间，涨幅相对较小。 • 服务器领域需求持续增长，薄布和特殊物种收入占比接近 34%，同比大幅 增长。高端手机和芯片板材领域表现良好，新能源汽车电子领域需求旺盛， 预计今年仍将保持强劲增长。军工、航空航天等其他用途相对稳定。 • 公司无新增产能，通过结构调整应对市场需求变化，采用接单式生产。高 端智能手机订单增加将带动持谣生产效率提升，改善收入、毛利率和净利。 市场偏好超薄布、极薄布，公司积极调整产线布局，满足高端产品需求。 • C3 产品价值远高于 D 类产品，公司希望增加 C3 产品比例，但受订单限制， 需依赖日本市场。公司正在进行产线切换，目标是最大 ...

AI 时代的量化投资与产品策略 ——申万宏源·2025 资本 市场春季策略会 20250311 摘要 • 人工智能策略通过处理海量数据和复杂因子，显著提升了传统多因子模型 的局限性，尤其是在量价数据分析方面，能够处理传统模型无法企及的因 子数量级，从而优化投资决策。 • 大模型如 DeepSeek 和 ChatGPT 展现出初步的主观分析能力，为"主观 +量化"投资新模式提供可能，但其专家级水准仍需验证，且小市值股票 入选概率问题可通过组合优化控制市值风险。 • 资管行业对 AI 策略的接受度提高，基于统计模型的 AI 策略因业绩表现良 好而逐渐被认可，但推理型大语言模型能否达到专家级水平仍需观察和验 证。 • ETF 市场规模已突破 3.8 万亿元，华安基金致力于提供 ETF 产品及解决方 案，关注 smart beta 策略，通过行业轮动和资产配置模型实现稳健收益， 并提供专业化服务。 • 华安基金的资产配置策略以稳健收益为目标，偏重债券投资，并通过全球 大类资产配置模型和 BLB 模型优化风险收益，同时结合定性分析进行市场 判断。 Q&A AI 技术在量化投资中的应用有哪些历史背景和发展路径？ 量化投资 ...

2025-03-11 14:48 记录_译文 2025 年 03 月 11 日 14:48 让我们从回顾 2024 年这一令人兴奋的旅程开始，这是水力住宅实现转型和重大突破的一年，净收入达 到了创纪录的高度，这一成就得益于我们在加速技术和机器人领域的轻量化应用的推动。 我们巩固了我们的行业领导地位，在 2024 年实现了超过 50 万单位的出货量，连续四年每年增长超过 一倍，展现了令人印象深刻的增长势头。 根据 2024 年便携式激光雷达市场占有率分析报告，我们公司不仅在全球激光雷达行业中交付了最强劲 的财务业绩，而且拥有最高的净收入和出色的毛利率，这得益于我们在激光雷达行业的领先地位。 最值得注意的是，我们将历史作为世界上第一激光雷达。 我们公司将实现全年净利润无差距增长，同时，通过稳健的运营和积极的净值管理，进一步加强了我们 无与伦比的财务领导地位，使我们在同行业中独树一帜。 第三，我们预计实现 2-3.5 亿的盈利。 中国在电气化领域处于领先地位，随着电动汽车成为新常态，2024 年电动汽车将占据近 50% 的乘用 车市场份额。竞争焦点正转向助力车辆智能化的发展。高盛预计，随着新能源汽车市场的激烈竞争 ...

March 11, 2025 America s Missing The New Labor Economy Robotics Part 1 //China's Dominance Paybook, Genera Purpose Robotics s The Hoy Grai, Robotic Systems Breakdown, Suppy Chain 更多一手调研纪要和研报数据加V：shuinu9870 更多一手调研纪要和研报数据加V：shuinu9870 更多一手调研纪要和研报数据加V：shuinu9870 更多一手调研纪要和研报数据加V：shuinu9870 更多一手调研纪要和研报数据加V：shuinu9870 更多一手调研纪要和研报数据加V：shuinu9870 Hardships, The West s Positioned Backward And Covering Their Eyes, China's Cear Path to Fu Scae Automation, Ca For Action 5 minutes 更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 to China, ...